title: Ð Ð°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ° Ð½Ð¾Ð²Ð¾Ð³Ð¾ Ð¾Ð½ÐºÐ¾Ð»Ð¸ÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð²Ð¸ÑÑÑÐ° Ð½Ð° Ð±Ð°Ð·Ðµ Ð¿ÑÐ¾ÑÑÐ¾Ð³Ð¾ Ð²Ð¸ÑÑÑÐ° Ð³ÐµÑÐ¿ÐµÑÐ° ÑÐµÐ»Ð¾Ð²ÐµÐºÐ° ÑÐ¸Ð¿Ð° 1
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Development of a noveloncolytic virus based on herpes simplex virus type 1
Creators: name: Ð Ð¾Ð¼Ð°Ð½ÑÑÐº, ÐÐ»Ð¸Ð·Ð°Ð²ÐµÑÐ°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2022
Subjects: ÐÐ¸Ð¾ÑÐµÑ Ð½Ð¾Ð»Ð¾Ð³Ð¸Ñ
ÐÐ¸ÑÑÑÐ¾Ð»Ð¾Ð³Ð¸Ñ
Ð¾Ð½ÐºÐ¾Ð»Ð¸ÑÐ¸ÑÐµÑÐºÐ¸Ðµ Ð²Ð¸ÑÑÑÑ
Ð²Ð¸ÑÑÑ Ð¿ÑÐ¾ÑÑÐ¾Ð³Ð¾ Ð³ÐµÑÐ¿ÐµÑÐ°
ÑÐ°Ðº
Ð¼ÐµÐ»Ð°Ð½Ð¾Ð¼Ð°
Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð²Ð¸ÑÑÑÐ½Ð¾Ð³Ð¾ ÐÐÐ
oncolytic viruses
herpes simplex virus
cancer
melanoma
viral DNA extraction

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ HSV 144/70, Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð½Ð¾Ð³Ð¾ Ð² ÐºÐ»Ð¸Ð½Ð¸ÑÐµÑÐºÐ¸Ñ ÑÑÐ»Ð¾Ð²Ð¸Ñ Ñ Ð±Ð¾Ð»ÑÐ½Ð¾Ð³Ð¾ Ð² UZ Ghent, ÐµÐ³Ð¾ Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð¸Ñ Ð¸ ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐµ. Ð ÑÐ°ÐºÐ¶Ðµ, Ð¸Ð´ÐµÐ½ÑÐ¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¸ ÐµÐ³Ð¾ ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð³ÐµÐ½Ð¾Ð², ÑÐ°ÐºÐ¸Ñ ÐºÐ°Ðº ICP 6 Ð¸ ICP 34.5 Ð¿ÑÑÐµÐ¼ ÐÐ¦Ð  Ð°Ð¼Ð¿Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¸ Ð¸ Ð£Ð¤ Ð²Ð¸Ð·ÑÐ°Ð»Ð¸Ð·Ð°ÑÐ¸Ð¸ Ñ Ð¸Ñ Ð´Ð°Ð»ÑÐ½ÐµÐ¹ÑÐ¸Ð¼ Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð¸ÐµÐ¼ Ð¸ ÑÐºÐµÐ²ÐµÐ½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸ÐµÐ¼. Ð ÑÐ¾Ð´Ðµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°ÑÐµÐ»ÑÑÐºÐ¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ»Ð° Ð¿ÑÐ¾Ð¸Ð·Ð²ÐµÐ´ÐµÐ½Ð° ÑÐ¸ÑÑÐ°ÑÐ¸Ñ Ð´Ð²ÑÑ Ð²Ð¸ÑÑÑÐ¾Ð², Ð±ÑÐ» Ð¾Ð¿ÑÐ¸Ð¼Ð¸Ð·Ð¸ÑÐ¾Ð²Ð°Ð½ Ð¿ÑÐ¾ÑÐ¾ÐºÐ¾Ð» Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð¸Ñ Ð²Ð¸ÑÑÑÐ½Ð¾Ð¹ ÐÐÐ; ÑÐ¸Ð½Ð°Ð»ÑÐ½Ð°Ñ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ñ Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð½Ð¾Ð¹ ÐÐÐ ÑÐ¾ÑÑÐ°Ð²Ð¸Ð»Ð° 542Â Ð½Ð³/Ð¼ÐºÐ». ÐÐµÐ½ ICP 6 Ð±ÑÐ» Ð¸Ð´ÐµÐ½ÑÐ¸ÑÐ¸ÑÐ¸ÑÐ¾Ð²Ð°Ð½ Ð¿ÑÐ¸ Ð¿Ð¾Ð¼Ð¾ÑÐ¸ ÐÐ¦Ð  Ð°Ð¼Ð¿Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¸ Ð¸ ÑÐµÐºÐ²ÐµÐ½Ð¸ÑÐ¾Ð²Ð°Ð½ ÐºÐ¾Ð¼Ð¿Ð°Ð½Ð¸ÐµÐ¹ eurofins genomics. Ð¡Ð¸ÐºÐ²ÐµÐ½Ñ Ð³ÐµÐ½Ð° ICP 6 HSV 144/70 Ð±ÑÐ» ÑÑÐ°Ð²Ð½ÐµÐ½ Ñ Ð¸Ð·Ð²ÐµÑÑÐ½ÑÐ¼ ÑÐ¸ÐºÐ²ÐµÐ½ÑÐ¾Ð¼ Ð³ÐµÐ½Ð° ICP 6 HSV F. Ð¡ÑÐ°Ð²Ð½ÐµÐ½Ð¸Ðµ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð»Ð¾, ÑÑÐ¾ Ð³ÐµÐ½Ñ Ð±ÑÐ»Ð¸ Ð¿ÑÐ°ÐºÑÐ¸ÑÐµÑÐºÐ¸ Ð³Ð¾Ð¼Ð¾Ð»Ð¾Ð³Ð¸ÑÐ½Ñ. ÐÐ´Ð½Ð°ÐºÐ¾, Ð³ÐµÐ½ ICP 34.5 Ð½Ðµ Ð±ÑÐ» Ð¸Ð´ÐµÐ½ÑÐ¸ÑÐ¸ÑÐ¸ÑÐ¾Ð²Ð°Ð½, Ð¿Ð¾ÑÑÐ¾Ð¼Ñ ÑÑÐµÐ±ÑÑÑÑÑ Ð´Ð°Ð»ÑÐ½ÐµÐ¹ÑÐ¸Ðµ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÑ Ð´Ð»Ñ Ð¾Ð±Ð½Ð°ÑÑÐ¶ÐµÐ½Ð¸Ñ Ð¸ Ð¸Ð´ÐµÐ½ÑÐ¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¸ Ð³ÐµÐ½Ð° ICP 34.5 Ð² Ð³ÐµÐ½Ð¾Ð¼Ðµ HSV 144/70. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð´Ð°Ð½Ð½Ð¾Ð¹ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°ÑÐµÐ»ÑÑÐºÐ¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ» Ð¾ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸Ð·Ð¾Ð²Ð°Ð½ Ð³ÐµÐ½ ICP 6 Ð² Ð²Ð¸ÑÑÑÐµ HSV-1, Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð½Ð¾Ð³Ð¾ Ð² ÐºÐ»Ð¸Ð½Ð¸ÑÐµÑÐºÐ¸Ñ ÑÑÐ»Ð¾Ð²Ð¸ÑÑ (HSV 144/70), Ð¸ ÑÐ°ÐºÐ¸Ð¼ Ð¾Ð±ÑÐ°Ð·Ð¾Ð¼, Ð²Ð½ÐµÑÐµÐ½ Ð·Ð½Ð°ÑÐ¸ÑÐµÐ»ÑÐ½ÑÐ¹ Ð²ÐºÐ»Ð°Ð´ Ð² ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÑ Ð½Ð¾Ð²Ð¾Ð³Ð¾ Ð¾Ð½ÐºÐ¾Ð»Ð¸ÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð²Ð¸ÑÑÑÐ° Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ HSV-1.
description: The given work is devoted to the study of HSV 144/70, isolated from a patient in a clinical setting in UZ Ghent, itâs isolation and characterization. Moreover, the identification of its specific genes, such as ICP 6 and ICP 34.5 genes by amplification using PCR and visualization with UV electrophoresis with their further isolation and sequencing, were also of interest. In the course of the research work, titration of two viruses was carried out, the DNA extraction protocol was optimized; the resulting DNA concentration was 542Â ng/Âµl. The ICP 6 gene was identified using PCR amplification and sequenced by eurofins genomics. The ICP 6 gene sequencing of the HSV 144/70 was compared with known ICP 6 gene sequence of the HSV F. The comparison showed that they were mostly homologue. However, the ICP 34.5 gene was not identified, therefore further experiments are required for detection and identification of the ICP 34.5 gene in the HSV 144/70 genome. The results of this research work led to the characterization of ICP6 in a clinical derived HSV-1 (HSV 144/70) and therefore made a significant contribution to the development of a novel HSV-1 based oncolytic virus.